EP1271 Prognostic implications of histological tumor regression (Böhm´s score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma

Introduction/Background Primary objective of this study was to determine prognostic significance of Bohm´s histopathological regression score in patients who received neoadjuvant chemotherapy (NACT) for treatment of high grade serous (HGS) tubal & ovarian carcinoma. Methodology This was a retrospective cohort study of patients who received NACT between 2010 and 2015. The 3 point histopathological regression score of Bohm was used to classify chemotherapy response. Survival outcomes between the 3 different subgroups was analysed and compared with standard clinico-pathological variables using the Cox proportional hazards model and log-rank test. Results Study cohort comprised 111 patients. Chemotherapy response score (CRS) 3 was observed in 47 (42.4%) and CRS 1and CRS 2 in 22 (19.8%) and 42 (37.8%) women respectively. Women with CRS score of 1 and 2 combined showed a three-fold increased risk of progression on both univariate and multivariate assessment (HR 3.54; C.I 2.19–5.72, p Conclusion CRS is an independent prognosticator of survival and reliable predictor of relapse within 6 months in advanced high grade serous tubal and ovarian carcinoma patients receiving NACT. Disclosure Nothing to disclose